SML4151

BI-2865

≥98% (HPLC), powder

• Synonim(y): (4S)-2-Amino-4,5,6,7-tetrahydro-4-methyl-4-[3-[4-[(1S)-1-[(2S)-1-methyl-2-pyrrolidinyl]ethoxy]-2-pyrimidinyl]-1,2,4-oxadiazol-5-yl]- benzo[b]thiophene-3-carbonitrile, (S)-2-amino-4-methyl-4-(3-(4-((S)-1-((S)-1-methylpyrrolidin-2-yl)ethoxy)pyrimidin-2-yl)-1,2,4-oxadiazol-5-yl)-4,5,6,7-tetrahydrobenzo[b]thiophene-3-carbonitrile
• Wzór empiryczny (zapis Hilla): C₂₃H₂₇N₇O₂S
• Numer CAS: 2937327-93-8
• Masa cząsteczkowa: 465.57
• MDL number: MFCD35067897
• NACRES: NA.21
• Assay: ≥98% (HPLC)
• Form: powder

Właściwości

• Quality Segment: 100
• assay: ≥98% (HPLC)
• form: powder
• color: white to beige
• solubility: DMSO: 2 mg/mL, clear
• storage temp.: -10 to -25°C
• SMILES string: NC(S1)=C(C#N)C2=C1CCC[C@]2(C)C3=NC(C4=NC(O[C@@H](C)[C@]5([H])CCCN5C)=CC=N4)=NO3

Opis

Application

BI-2865 may be used for studying the Kirsten rat sarcoma virus (KRAS)signaling pathways and their role in cancer. Its selective inhibition of KRAS isused to probe the biological functions of KRAS, its mutants, and downstreamsignaling pathways to gain a deeper understanding of KRAS-related oncogenesis.

Biochem/physiol Actions

BI-2865 is a cell penetrant, selective and potent pan-KRAS inhibitor, which binds with high affinity to the inactive state of KRAS and KRAS mutants. BI-2865 blocks nucleotide exchange to prevent the activation of wild-type KRAS and a broad range of KRAS mutants. It inhibits downstream signaling and growth in cancer cells harboring mutant KRAS. It does not bind to NRAS and HRAS.

Ta strona może zawierać tekst przetłumaczony maszynowo.

Informacja o środkach bezpieczeństwa

• pictograms: GHS07
• signalword: Warning
• hcodes: H302,H315
• pcodes: P264 - P280 - P301 + P312 - P302 + P352 - P332 + P313 - P362 + P364
• Hazard Classifications: Acute Tox. 4 Oral - Skin Irrit. 2
• Klasa składowania: 11 - Combustible Solids
• flash_point_f: Not applicable
• flash_point_c: Not applicable